| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SHMT2 |
| Uniprot No | P34897 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-504aa |
| 氨基酸序列 | N AAQTQTGEAN RGWTGQESLS DSDPEMWELL QREKDRQCRG LELIASENFC SRAALEALGS CLNNKYSEGY PGKRYYGGAE VVDEIELLCQ RRALEAFDLD PAQWGVNVQP YSGSPANLAV YTALLQPHDR IMGLDLPDGG HLTHGYMSDV KRISATSIFF ESMPYKLNPK TGLIDYNQLA LTARLFRPRL IIAGTSAYAR LIDYARMREV CDEVKAHLLA DMAHISGLVA AKVIPSPFKH ADIVTTTTHK TLRGARSGLI FYRKGVKAVD PKTGREIPYT FEDRINFAVF PSLQGGPHNH AIAAVAVALK QACTPMFREY SLQVLKNARA MADALLERGY SLVSGGTDNH LVLVDLRPKG LDGARAERVL ELVSITANKN TCPGDRSAIT PGGLRLGAPA LTSRQFREDD FRRVVDFIDE GVNIGLEVKS KTAKLQDFKS FLLKDSETSQ RLANLRQRVE QFARAFPMPG FDEH |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于SHMT2重组蛋白的参考文献及其摘要概括：
1. **"Structural insights into mitochondrial serine hydroxymethyltransferase (SHMT2) by recombinant expression and crystallography"**
*作者：Anderson et al.*
摘要：报道了人源SHMT2重组蛋白在大肠杆菌中的高效表达与纯化方法，通过X射线晶体学解析了其三维结构，揭示了辅酶磷酸吡哆醛结合位点及底物通道特征。
2. **"SHMT2 knockdown induces ROS accumulation and mitochondrial dysfunction in cancer cells via recombinant protein interaction studies"**
*作者：Kim et al.*
摘要：通过重组SHMT2蛋白与癌细胞裂解液的互作实验，发现SHMT2通过调控叶酸代谢维持线粒体氧化还原稳态，其缺失导致活性氧(ROS)积累和细胞凋亡。
3. **"Recombinant human SHMT2 as a therapeutic target in EGFR-driven lung adenocarcinoma"**
*作者：Zhang et al.*
摘要：利用重组SHMT2蛋白进行高通量药物筛选，发现其抑制剂可阻断EGFR突变肺癌细胞的核苷酸合成，显著增强化疗敏感性。
注：上述文献信息为示例性概括，实际文献需通过PubMed或Web of Science检索确认。近年研究多聚焦于SHMT2在肿瘤代谢重编程中的作用机制及靶向策略。
Serine hydroxymethyltransferase 2 (SHMT2) is a mitochondrial enzyme central to one-carbon metabolism, a critical pathway supporting nucleotide synthesis, methylation reactions, and redox homeostasis. It catalyzes the reversible conversion of serine and tetrahydrofolate (THF) to glycine and 5.10-methylene-THF, linking amino acid metabolism with folate cycling. SHMT2’s activity is particularly vital in rapidly proliferating cells, such as cancer cells, where it helps meet the high demand for purines, thymidylate, and NADPH. Dysregulation of SHMT2 has been implicated in tumor progression, chemoresistance, and metabolic adaptation in hypoxic environments, making it a potential therapeutic target.
Recombinant SHMT2 protein, produced through heterologous expression systems like *E. coli* or mammalian cell cultures, enables detailed biochemical and structural studies. Its purified form is used to investigate enzyme kinetics, substrate specificity, and allosteric regulation, often in combination with inhibitors or folate analogs. Structural analyses (e.g., X-ray crystallography) of recombinant SHMT2 have revealed insights into its catalytic mechanism and conformational dynamics, aiding drug design. Additionally, it serves as a tool for cellular studies when delivered into SHMT2-deficient models to rescue phenotypes or explore metabolic dependencies.
Research on recombinant SHMT2 also extends to biomarker development, as its overexpression in tumors correlates with poor prognosis. Inhibitors targeting SHMT2 are being explored for anticancer therapies, with recombinant protein platforms accelerating high-throughput screening. Beyond oncology, SHMT2 variants are studied in neurodevelopmental disorders and mitochondrial diseases, highlighting its broad physiological relevance. Overall, recombinant SHMT2 is a key reagent for dissecting one-carbon metabolism and translating these insights into clinical applications.
×
